ReviewGut and liver2022
Prolonged QT Interval in Cirrhosis: Twisting Time?
Review in Gut and liver, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.
- Cardiovascular risk assessment and predictors of cardiac decompensation after transjugular intrahepatic portosystemic shunt in patients with cirrhosis.World journal of gastroenterology · 2025Pooled it
- Bradycardia and Other Arrhythmias in Patients With Hepatorenal Syndrome-Acute Kidney Injury Following Terlipressin Treatment: A Pooled Analysis of Three North American Phase III Clinical Studies.Alimentary pharmacology & therapeutics · 2025Trial
- [Research progress on the pathogenesis and clinical treatment of cirrhotic cardiomyopathy].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2026Review
- QTc interval prolongation in ICU patients: risk assessment and predictors.The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology · 2026Article
- Factors influencing QT interval prolongation during rifampicin-resistant tuberculosis treatment: a multicenter real-world study from China.BMC infectious diseases · 2025Article
- Impact of Thyroid Hormone Imbalance on Electrocardiographic Parameters: Systematic Review and Meta-Analysis.Journal of clinical medicine · 2025Review
- Inflammation and Mitochondrial Dysfunction in Cirrhotic Cardiomyopathy: Therapeutic Implications.Journal of clinical and translational hepatology · 2025Article
- Decoding Silent Signals: A Systematic Review of ECG and the Quest for an Early Diagnosis of Cirrhotic Cardiomyopathy.Cureus · 2025Review
- Electrocardiogram-based diagnosis of liver diseases: an externally validated and explainable machine learning approach.EClinicalMedicine · 2025Article
- Risk Stratification of QTc Prolongations in Hospitalized Cardiology and Gastroenterology Patients Using the Tisdale Score-A Retrospective Analysis.Journal of clinical medicine · 2025Article
- The Cardiomyocyte in Cirrhosis: Pathogenic Mechanisms Underlying Cirrhotic Cardiomyopathy.Reviews in cardiovascular medicine · 2024Review
- Reply to: Correspondence on "Cardiomyopathy in cirrhosis: From pathophysiology to clinical care".JHEP reports : innovation in hepatology · 2024Article
- From genes to clinical management: A comprehensive review of long QT syndrome pathogenesis and treatment.Heart rhythm O2 · 2024Review
- Therapies for Cirrhotic Cardiomyopathy: Current Perspectives and Future Possibilities.International journal of molecular sciences · 2024Review
- Cardiomyopathy in cirrhosis: From pathophysiology to clinical care.JHEP reports : innovation in hepatology · 2024Review
- Propranolol can correct prolonged QT intervals in patients with cirrhosis.Frontiers in pharmacology · 2024Article
- How non-alcoholic fatty liver disease and cirrhosis affect the heart.Hepatology international · 2023Review
- Oxidative Mechanisms and Cardiovascular Abnormalities of Cirrhosis and Portal Hypertension.International journal of molecular sciences · 2023Review
- Corrected QT interval in cirrhosis: A systematic review and meta-analysis.World journal of hepatology · 2023Article
- Role of Galectin in Cardiovascular Conditions including Cirrhotic Cardiomyopathy.Pharmaceuticals (Basel, Switzerland) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 4 countries.
Funding
Abstract
Approximately 30% to 70% of patients with cirrhosis have QT interval prolongation. In patients without cirrhosis, QT prolongation is associated with an increased risk of ventricular arrhythmias, such as torsade de pointes (TdP). In cirrhotic patients, there is likely a significant association between the corrected QT (QTc) interval and the severity of liver disease, and possibly with increased mortality. We present a stepwise overview of the pathophysiology and management of acquired long QT syndrome in cirrhosis. The QT interval is mainly determined by ventricular repolarization. To compare the QT interval in time it should be corrected for heart rate (QTc), preferably by the Fridericia method. A QTc interval >450 ms in males and >470 ms in females is considered prolonged. The pathophysiological mechanism remains incompletely understood, but may include metabolic, autonomic or hormonal imbalances, cirrhotic heart failure and/or genetic predisposition. Additional external risk factors for QTc prolongation include medication (I
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.